HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Status:
Withdrawn
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion
chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and programmed
cell death protein-1 antibody compared with lenvtinib Alone in patients with hepatic arterial
infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib for
advanced hepatocellular carcinoma (HCC)
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Guangzhou No.12 People's Hospital Kaiping Central Hospital